GlassScriptPhysician profile
Martin Caha
NPI 1720548209
$7,461.58
in general payments reported to CMS, 2019-2025
30 companies · $2,427 in 2025
The $2,427 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,369 · 2023: $2,404 · 2024: $1,262 · 2025: $2,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,275 · Grant: $800 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,275.38 |
| Grant | $800.00 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,106.39 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $1,000.00 | 2022 | |
| Biocryst US Sales Co., LLC | $485.58 | 2022-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $471.82 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Dermavant Sciences, INC. | $450.27 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $313.83 | 2023-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $261.72 | 2025 | Neffy |
| Pharming Healthcare, INC. | $186.59 | 2024-2025 | Joenja, Ruconest |
| Blueprint Medicines Corporation | $186.41 | 2023-2025 | Ayvakit |
| Alk-Abello, INC | $182.99 | 2023-2025 | Ragwitek, Odactra, Grastek |
| Astrazeneca Pharmaceuticals LP | $182.93 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $169.37 | 2024-2025 | Hizentra, Andembry, Kcentra |
| Takeda Pharmaceuticals U.S.A., INC. | $165.31 | 2024-2025 | Cuvitru, Eohilia |
| Sanofi-Aventis U.S. LLC | $148.14 | 2024 | |
| Grifols USA, LLC | $125.48 | 2024-2025 | Xembify |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $125.00 | 2022 | |
| Alkermes, INC. | $117.28 | 2023 | Lybalvi |
| Sanofi US Services INC. | $117.10 | 2025 | |
| Incyte Corporation | $105.25 | 2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $95.89 | 2025 | |
| Amgen INC. | $83.10 | 2025 | Tezspire, Actimmune |
| Arcutis Biotherapeutics, INC. | $62.23 | 2025 | Zoryve |
| Ionis Pharmaceuticals, INC. | $57.63 | 2025 | Dawnzera |
| Horizon Therapeutics Plc | $56.11 | 2022 | |
| Lilly USA, LLC | $47.48 | 2025 | Ebglyss, Taltz |
| Insmed, INC. | $39.55 | 2025 | Arikayce |
| Gc Biopharma USA, INC. | $37.95 | 2024-2025 | Alyglo, Alyglo |
| Azurity Pharmaceuticals, INC. | $36.15 | 2025 | Alvesco |
| Greer Laboratories, INC. | $22.71 | 2025 | Oralair |
| Pfizer INC. | $21.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Caha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.